Screener
Altimmune ALT Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Altimmune in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Altimmune’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:13 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001326190-26-000040
| Line item | Three Months Ended / March 31, 2026 | Three Months Ended / March 31, 2025 |
|---|---|---|
| Accounts payable | (1,187) | 866 |
| Accrued expenses and other liabilities | (2,493) | (1,699) |
| Income tax and R&D incentive receivables | 518 | 1,297 |
| Net cash used in operating activities | (20,942) | (16,840) |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||
| Proceeds from sales and maturities of short-term investments | 39,622 | 38,040 |
| Purchases of short-term investments | (43,291) | (43,141) |
| Purchases of property and equipment | (21) | — |
Item 1. Financial Statements
FAQ
- What is Altimmune's operating cash flow?
- Altimmune (ALT) reported operating cash flow of -$20.94M in Q1 2026.
- How has Altimmune's operating cash flow changed year-over-year?
- Altimmune's operating cash flow decreased by 24.4% year-over-year, from -$16.84M to -$20.94M.
- What is the long-term trend for Altimmune's operating cash flow?
- Over 4 years (2021 to 2025), Altimmune's operating cash flow has grown at a -3.6% compound annual growth rate (CAGR), from -$78.24M to -$67.54M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Altimmune's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude